A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: A randomized phase I trial

British Journal of Clinical Pharmacology

Volumn 66, Issue 1, 2008, Pages 102-109

  Peppe, Jennifer ^a   Porzio, Andrew ^a   Davidson, David M ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Clostridium difficile; Hypokalaemia; Nosocomial diarrhoea; Safety and efficacy; Tolevamer

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; PLACEBO; TOLEVAMER;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION URGENCY; DOUBLE BLIND PROCEDURE; DRUG BINDING; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG FATALITY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN EXPERIMENT; LOADING DRUG DOSE; LOOSE FECES; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VITAL SIGN;

ADOLESCENT; ADULT; AGED; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; DRUG ADMINISTRATION SCHEDULE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; MALE; MIDDLE AGED; POLYMERS; TREATMENT OUTCOME;

EID: 44949249151     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03151.x     Document Type: Article

References (38)

1. Hogenauer C, Hammer HF, Krejs GJ, Reisinger EC. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis 1998 27 : 702 10.
2. Pothoulakis C, LaMont JT. Clostridium difficile colitis and diarrhea. Gastroenterol Clin North Am 1993 22 : 623 37.
3. Kelly CP, LaMont JT. Clostridium difficile infection. Annu Rev Med 1998 49 : 375 90.
4. Buchner AM, Sonnenberg A. Epidemiology of Clostridium difficile infection in a large population of hospitalized US military veterans. Dig Dis Sci 2002 47 : 201 7.
5. Valiquette L, Low DE, Pepin J, McGeer A. Clostridium difficile infection in hospitals: a brewing storm. Can Med Assoc J 2004 171 : 27 9.
6. Wilcox MH, Smyth ET. Incidence and impact of Clostridium difficile infection in the UK, 1993-1996. J Hosp Infect 1998 39 : 181 7.
7. Archibald LK, Banerjee SN, Jarvis WR. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis 2004 189 : 1585 9.
8. Eggertson L, Sibbald B. Hospitals battling outbreaks of C. difficile. Can Med Assoc J 2004 171 : 19 21.
9. Hyland M, Ofner-Agostini M, Miller M. N-CDAD in Canada: results of the Canadian nosocomial infection surveillance program 1997 N-CDAD prevalence surveillance project. Can J Infect Dis 2001 12 : 81 8.
10. Loo VG, Libman MD, Miller MA, Bourgault AM, Frenette CH, Kelly M, Michaud S, Nguyen T, Poirier L, Vibien A, Horn R, Laflamme PJ, Rene P. Clostridium difficile: a formidable foe. Can Med Assoc J 2004 171 : 47 8.
11. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005 366 : 1079 94.
12. McDonald LC, Killgore GE, Thompson A, Owens RC Kazakova SV, Sambol SP, Johnson S, Gerding DN. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005 353 : 2433 41.
13. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, Rene P, Monczak Y, Dascal A. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005 353 : 2442 9.
14. Bartlett JG, Peri TM. The new Clostridium difficile - what does it mean? N Engl J Med 2005 353 : 2503 5.
15. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994 330 : 257 62.
16. Fiorentini C, Thelestam M. Clostridium difficile toxin A and its effects on cells. Toxicon 1991 29 : 543 67.
17. Rothman SW, Brown JE, Diecidue A, Foret DA. Differential cytotoxic effects of toxins A and B isolated from Clostridium difficile. Infect Immun 1984 46 : 324 31.
18. Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993 269 : 71 5.
19. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997 24 : 324 33.
20. Yassin SF, Young-Fadok TM, Zein NN, Pardi DS. Clostridium difficile-associated diarrhea and colitis. Mayo Clin Proc 2001 76 : 725 30.
21. Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, Godin D, Bourassa C. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005 40 : 1591 7.
22. Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, Hamill RJ. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005 40 : 1586 90.
23. Gerding DN. Metronidazole for Clostridium difficile-associated disease: is it okay for mom? Clin Infect Dis 2005 40 : 1598 600.
24. Braunlin W, Xu Q, Hook P, Fitzpatrick R, Klinger JD, Burrier R, Kurtz CB. Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Biophys J 2004 87 : 534 9.
25. Kurtz CB, Cannon EP, Brezzani A, Pitruzzello M, Dinardo C, Rinard E, Acheson DW, Fitzpatrick R, Kelly P, Shackett K, Papoulis AT, Goddard PJ, Barker RH Palace GP, Klinger JD. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother 2001 45 : 2340 7.
26. Davidson D, Peppe J, Louie T. A phase 2 study of the toxin binding polymer tolevamer in patients with C. difficile associated diarrhea [poster]. Paper presented at: First International Clostridium difficile Symposium (FICDS), May 5-8, 2004, Gozd Matuljek, Slovenia.
27. Louie TL, Peppe J, Watt CK, Johnson D, Mohammed R, Dow G, Weiss K, Simon S, John JF Garber G, Chasen-Taber S, Davidson DM for the Tolevamer Study Investigator Group. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006 43 : 411 20.
28. Barker RH Dagher R, Davidson DM, Marquis JK. Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physiochemical properties. Alimen Pharmacol Ther 2006 24 : 1525 34.
29. Cohen JM, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice. Arch Intern Med 2000 160 : 2429 36.
30. Fekety R, Silva J, Buggy B, Deery HG. Treatment of antibiotic-associated colitis with vancomycin. J Antimicrob Chemother 1984 14 (Suppl. D 97 102.
31. Fekety R, Silva J, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989 86 : 15 9.
32. Gerding DN. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin Infect Dis 1997 25 (Suppl. 2 S206 10.
33. Pelaez T, Alcala L, Alonso R, Rodriguez-Creixems M, Garcia-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002 46 : 1647 50.
34. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 1997 92 : 739 50.
35. Johnson S, Gerding DN. Clostridum difficile-associated diarrhea. Clin Infect Dis 1998 26 : 1027 34.
36. Bartlett JG. Antibiotic-associated diarrhea. N Engl J Med 2002 346 : 334 9.
37. Kasten MJ. Clindamycin, metronidazole, and chloramphenicol. Mayo Clin Proc 1999 74 : 825 33.
38. Louie T, Gerson M, Grimard D, Johnson S, Poirier A, Weiss K, Peppe J, Donovan J, Davidson D for the Polymer Alternative for CDAD Treatment (PACT) Investigator. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2007 September 17-20; Chicago, Illinois. Conference Poster 3826.